Psonet

New therapies in development for psoriasis: what changes in clinical research?

Biological drugs have been considered a scientific and clinical progress in the treatment of psoriasis. However, their role can be fully assessed only when randomized controlled trials will compare them with each other and with conventional drugs, and when data efficacy and safety in the long term will become available  

Meanwhile, search for new molecules carries on and in the near future new therapies will become available: some of these drugs are already used in clinical Phase II and III, while others are in early stages of development.

For drugs close to market, it seems desirable to rely on post-marketing evaluation systems: studies of efficacy and long-term safety, comparison and for assessing outcomes (end point) clinically relevant outcomes, not surrogates.

Here you can find an overview of the state of the art of these new molecules. Information on clinical trials in progress will be regularly updated.

Mechanism	Compound	Administration route	Phase	Sponsor
TNF alfa inhibitor	Certolizumab pegol (Cimzia)	Subcutaneous	II	UCB
	CF101	Oral	II/III	Can-Fite BioPharma
	ART621	Subcutaneous	I/II	Arana Therapeutics
Cytokine inhibitor - phosphodiesterase 4 inhibitor	CC 10004 (Apremilast)	Oral	II	Duke University
IL-12/23 inhibitor	CNTO 1275 (Ustekinumab)	Intravenous, subcutaneous	III	Centocor  Medarex
	ABT 874 (Briakinumab)	Subcutaneous	III	Abbott, Wieth
IL-15 inhibitor	AMG 714	Subcutaneous	II	Amgen
Calcineurin inhibitor	ISA 247 (Voclosporin)	Oral	III	Isotechnika
Retinoic acid regulator	R115866 (Rambazole)	Oral, topical	II	Barrier Therapeutic/ Stiefel
PNP (purine nucleotide phosphorilase) inhibitor	R3421 / BCX-4208	Oral	II	Hoffmann-La Roche
Anti-inflammatory	ILV-094 (Fezakinumab)	Subcutaneous, intravenous	I	Wyeth
Immune regulator  anti CD20 inhibitor	Rituximab (Rituxan)	Intravenous	II	Swedish Medical Center Genentech
T cell regulator	Abatacept / BMS188667 (Orencia)	Intravenous	II	Bristol-Meyer Squibb
Cytokine inhibitor	CP-690,550 (Tasocitinib)	Oral	III	Pfizer
Non conventional treatment	Reiki		I	South Devon Healthcare NHS Foundation Trust (UK)
Vitamin D2	Doxercalciferol (Hectorol)	Oral	II	Genzyme
IL-17 inhibitor	AIN457 (Secukinumab)	Intravenous, subcutaneous	II	Novartis
Immune regulator PKC inhibitor	AEB071	Oral	II	Novartis
Cathepsin S inhibitor	RWJ-445380	Oral	II	Alza Corporation, DE, USA
T cell regulator	AbGn-168	Intravenous	I	Boehringer Ingelheim Pharmaceuticals
Anti-inflammatory	Leo 22811	Oral	I	Leo Pharma
IL-17 inhibitor	AMG 827	Intravenous, subcutaneous	I	Amgen
Immune regulator	BTT 1023	Intravenous	I	Biotie Therapies Corp.
Immune regulator	CNTO1959	Intravenous, subcutaneous	I	Centocor
Folate inhibitor	Aminopterin	Oral	I	Syntrix Biosynthesis
Anti-inflammatory	VB-201	Oral	II	Vascular Biogenics
Immune regulator	BT061	Intravenous, subcutaneous	II	Biotest
Diet	Algae	Oral	III	Manitoba University
Hypoglycemic agent	Pioglitazone	Oral		Cairo University
Weight loss	Weight loss			The University of Texas Health Science Center, Houston
Fabric	TEPSO		II	Lenzi Egisto SPA
Immune regulator	ACT-128800	Oral	II	Actelion
Retinoic acid	Alitretinoin	Oral	II	Basilea Pharmaceutica
IL-23 inhibitor	SCH900222	Subcutaneous	II	Schering Plough
Small molecule	FP187	Oral	II	Forward-Pharma GmbH
Algae (beta-carotene)	Alga Dunaliella Bardawil	Oral		Sheba Medical Center
Hypoglycemic agent	Liraglutide	Subcutaneous		Annesofie Faurschou
New molecule	RO5310074	Intravenous	I	Hoffmann-La Roche
IL-23 inhibitor	LY2439821	Subcutaneous	III	Eli Lilly and Company
Anti-inflammatory	SRT2104	Oral	II	Sirtris, a GSK Company
New molecule	Apo805K1	Oral	II	ApoPharma
New molecule	KHK4827	Subcutaneous Intravenous	I	Kyowa Hakko Kirin Company, Limited
JAK1-JAK2 inhibitor	LY3009104	Oral	II	Eli Lilly and Company

Read more

You can find more information about ongoing clinical trials and drugs in development at the following addresses:

http://www.clinicaltrials.gov/

http://www.psoriasis.org/research/pipeline/chart.php

http://controlled-trials.com/ 

http://www.who.int/ictrp/en/

http://www.anzctr.org.au/default.aspx